+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Overactive Bladder - Pipeline Review, H1 2020

  • ID: 5024771
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 127 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aetas Pharma Co Ltd
  • DelNova Inc
  • Evestra Inc
  • Imbrium Therapeutics LP
  • Korea United Pharm Inc
  • Merck & Co Inc
  • MORE
Overactive Bladder - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 2020, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 8, 3, 12, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aetas Pharma Co Ltd
  • DelNova Inc
  • Evestra Inc
  • Imbrium Therapeutics LP
  • Korea United Pharm Inc
  • Merck & Co Inc
  • MORE
  • Introduction
  • Overactive Bladder - Overview
  • Overactive Bladder - Therapeutics Development
  • Overactive Bladder - Therapeutics Assessment
  • Overactive Bladder - Companies Involved in Therapeutics Development
  • Overactive Bladder - Drug Profiles
  • Overactive Bladder - Dormant Projects
  • Overactive Bladder - Discontinued Products
  • Overactive Bladder - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Overactive Bladder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Overactive Bladder - Pipeline by Aetas Pharma Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Allergan Plc, H1 2020
  • Overactive Bladder - Pipeline by Astellas Pharma Inc, H1 2020
  • Overactive Bladder - Pipeline by DelNova Inc, H1 2020
  • Overactive Bladder - Pipeline by Dompe Farmaceutici SpA, H1 2020
  • Overactive Bladder - Pipeline by Dong-A ST Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by DongKoo Bio & Pharma Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Evestra Inc, H1 2020
  • Overactive Bladder - Pipeline by Exxel Pharma Inc, H1 2020
  • Overactive Bladder - Pipeline by FemmePharma Global Healthcare Inc, H1 2020
  • Overactive Bladder - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Hydra Biosciences Inc, H1 2020
  • Overactive Bladder - Pipeline by Imbrium Therapeutics LP, H1 2020
  • Overactive Bladder - Pipeline by Ion Channel Innovations LLC, H1 2020
  • Overactive Bladder - Pipeline by J2H Biotech, H1 2020
  • Overactive Bladder - Pipeline by Johnson & Johnson, H1 2020
  • Overactive Bladder - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Korea United Pharm Inc, H1 2020
  • Overactive Bladder - Pipeline by KYORIN Holdings Inc, H1 2020
  • Overactive Bladder - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Lipella Pharmaceuticals Inc, H1 2020
  • Overactive Bladder - Pipeline by Medytox Inc, H1 2020
  • Overactive Bladder - Pipeline by Merck & Co Inc, H1 2020
  • Overactive Bladder - Pipeline by Mezzion Pharma Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Recordati SpA, H1 2020
  • Overactive Bladder - Pipeline by Revance Therapeutics Inc, H1 2020
  • Overactive Bladder - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by TheraVida Inc, H1 2020
  • Overactive Bladder - Pipeline by Velicept Therapeutics Inc, H1 2020
  • Overactive Bladder - Pipeline by XuanZhu Pharma Co Ltd, H1 2020
  • Overactive Bladder - Dormant Projects, H1 2020
  • Overactive Bladder - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Overactive Bladder - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Overactive Bladder - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Overactive Bladder - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Overactive Bladder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aetas Pharma Co Ltd
  • Allergan Plc
  • Astellas Pharma Inc
  • DelNova Inc
  • Dompe Farmaceutici SpA
  • Dong-A ST Co Ltd
  • DongKoo Bio & Pharma Co Ltd
  • Evestra Inc
  • Exxel Pharma Inc
  • FemmePharma Global Healthcare Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Hydra Biosciences Inc
  • Imbrium Therapeutics LP
  • Ion Channel Innovations LLC
  • J2H Biotech
  • Johnson & Johnson
  • Kissei Pharmaceutical Co Ltd
  • Korea United Pharm Inc
  • KYORIN Holdings Inc
  • Kyorin Pharmaceutical Co Ltd
  • Lipella Pharmaceuticals Inc
  • Medytox Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • Recordati SpA
  • Revance Therapeutics Inc
  • Taiho Pharmaceutical Co Ltd
  • TheraVida Inc
  • Velicept Therapeutics Inc
  • XuanZhu Pharma Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll